In recent years, the treatment modalities for advanced HCC patients with IVCTT and/or RA include thrombectomy, transhepatic arterial chemotherapy embolization (TACE), targeted therapy and immunotherapy (checkpoint inhibitor of the programmed cell death protein-1, PD-1 inhibitor). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.